• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

Valeant Pharmaceuticals

Here are the pharma companies accused of blocking generic competition

May 17, 2018 By Sarah Faulkner

To prove a generic drug is as safe and effective as the branded version, pharmaceutical companies have to hand over upwards of 1,000 doses of the product to a generic developer. But if the manufacturer creating the generic drug cannot get its hands on enough sample, the development and testing process slows down. It could […]

Filed Under: Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: Actelion, Celgene, FDA, Gilead Sciences, GlaxoSmithKline plc, Johnson and Johnson, Novartis, Valeant Pharmaceuticals

Egalet teams up with Valeant division to promote pain-relief nasal spray

January 3, 2018 By Sarah Faulkner

Egalet (NSDQ:EGLT) has partnered with a division of Valeant Pharmaceuticals (NYSE:VRX), OraPharma, to co-promote its pain-relief nasal spray to dentists and oral surgeons in the U.S. Sprix nasal spray is a nonsteroidal anti-inflammatory drug designed for the short-term management of moderate to moderately-severe pain. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Drug-Device Combinations, Pain Management, Pharmaceutical, Wall Street Beat Tagged With: egalet, Valeant Pharmaceuticals

Ocular Therapeutix founder & CEO Sawhney to step down | Personnel Moves – April 13, 2017

June 23, 2017 By Sarah Faulkner

The president & CEO of Ocular Therapeutix (NSDQ:OCUL), Amarpreet Sawhney, is slated to step down from the company that he helped start in 2006. He will serve as the board’s executive chairman for 1 year, unless he decides to leave earlier. The company wrote in a regulatory filing that “his service will be automatically renewed for […]

Filed Under: Drug-Device Combinations, Pharmaceutical, Wall Street Beat Tagged With: Biogen, Bristol-Myers Squibb Co., etonpharmaceuticals, Nanotherapeutics, Novartis, oculartherapeutix, Personnel Moves, Pulmatrix Inc., Valeant Pharmaceuticals

Report: Valeant shopping sale of surgical eye biz

June 6, 2017 By Fink Densford

Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) is looking to sell its Bausch & Lomb division’s surgical product assets to Carl Zeiss Meditec (ETR:AFX), according to a Bloomberg report. The surgical eye assets could be worth approximately $2 billion, according to the report, with a possible agreement still weeks away. No final decisions have been made, and other interested […]

Filed Under: Business/Financial News, Optical/Ophthalmic, Surgical Tagged With: Valeant Pharmaceuticals

Valeant posts Q1 profit thanks to tax benefit, misses on revenue

May 9, 2017 By Sarah Faulkner

Shares in Valeant Pharmaceuticals (NYSE:VRX) rose more than 25% today after the company met earnings expectations on Wall Street, but missed on revenue with its 1st quarter results. The Canada-based company posted profits of $628 million, or $1.79 per share, on sales of $2.11 billion for the 3 months ended March 31, for bottom-line growth […]

Filed Under: MassDevice Earnings Roundup, Optical/Ophthalmic, Pharmaceutical, Wall Street Beat Tagged With: Valeant Pharmaceuticals

Bausch & Lomb wins FDA 510(k) for Vitesse open-port vitrectomy system

April 27, 2017 By Fink Densford

Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) subsidiary Bausch & Lomb said today it won FDA 510(k) clearance for its Vitesse hypersonic open port vitrectomy system. The Bridgewater, N.J.-based company touted the newly cleared system as the 1st and only hypersonic 100% open port vitrectomy system, and said it will be exclusively available on the Stellaris Elite vision enhancement […]

Filed Under: 510(k), Food & Drug Administration (FDA), Optical/Ophthalmic, Regulatory/Compliance Tagged With: Bausch + Lomb, Valeant Pharmaceuticals

FDA clears Bausch & Lomb’s Stellaris Elite cataract system

April 6, 2017 By Fink Densford

Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) subsidiary Bausch & Lomb said today it won FDA 510(k) clearance for its Stellaris Elite vision enhancement system. The system is a next-gen phacoemulsification cataract platform designed for cataract lens removal, and offers improved customization and precise aspiration control with predictive infusion management, Bausch & Lomb said. “We are pleased to continue […]

Filed Under: 510(k), Food & Drug Administration (FDA), Optical/Ophthalmic, Regulatory/Compliance Tagged With: Bausch + Lomb, Valeant Pharmaceuticals

Valeant, Ackman agree to split costs in shareholders class action

February 14, 2017 By Sarah Faulkner

Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) and William Ackman’s hedge fund Pershing Square Capital Management reportedly agreed to split litigation costs in a class action lawsuit brought on by shareholders over an alleged insider trading scheme in Allergan (NYSE:AGN)’s 2014 takeover bid. In June 2014, Valeant offered a tender bid for Allergan, which was followed by a 7 month-long […]

Filed Under: Legal News, Wall Street Beat Tagged With: Actavis, Allergan, Valeant Pharmaceuticals

Allergan pays $15m for failing to disclose Actavis ‘white knight’ offer

January 18, 2017 By Sarah Faulkner

The SEC said yesterday that Allergan (NYSE:AGN) will pay a $15 million fine for failing to disclose its 2014 merger talks with Actavis. In June 2014, Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) offered a tender bid for the Irvine, Calif.-based company which was followed by a 7 month-long hostile pursuit by Valeant and co-bidder Pershing Square Capital Management. In November […]

Filed Under: Legal News, Pharmaceutical, Wall Street Beat Tagged With: Actavis, Allergan, Valeant Pharmaceuticals

AARP report details increase in brand name drug prices

December 14, 2016 By Sarah Faulkner

The AARP Public Policy Institute released a report today showing that 2015 was the 4th straight year of double-digit average annual increases for widely used brand name drugs. The nonprofit organization also concluded that prices for brand name drugs increased almost 130 times faster than the 0.1% general inflation rate in 2015. The report, which […]

Filed Under: Drug-Device Combinations, Healthcare Reform, Pharmaceutical, Wall Street Beat Tagged With: Valeant Pharmaceuticals

California insurance board subpoenas Valeant

November 10, 2016 By Sarah Faulkner

Valeant Pharmaceuticals (NYSE:VRX) said yesterday that it received an investigative subpoena from the California Dept. of Insurance last month over its ties to a specialty pharmacy, Philidor Rx Services. The company is facing allegations that it used Philidor to force customers to pay higher prices for its drugs. The subpoena reportedly asked for materials such as documents […]

Filed Under: Drug-Device Combinations, Legal News, Pharmaceutical, Regulatory/Compliance, Respiratory Tagged With: Valeant Pharmaceuticals

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 9
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

May 27, 2022
Quick message - No DTW podcast, but plenty else to listen to over this weekend and next week.
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS